Pacira BioSciences, Inc. (PCRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300M 600M 900M Q3 '21: 513.3M Q4 '21: 541.5M Q1 '22: 580.5M Q2 '22: 614.3M Q3 '22: 654.1M Q4 '22: 666.8M Q1 '23: 669.2M Q2 '23: 669.2M Q3 '23: 665.7M Q4 '23: 675M Q1 '24: 681.8M Q2 '24: 690.3M Q3 '24: 695M Q4 '24: 701M Q1 '25: 702.8M Q2 '25: 705.8M Q3 '25: 716.8M Q4 '25: 726.4M Q1 '26: 734.9M Q2 '26: 746.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 250M 500M 750M Q3 '21: 376.8M Q4 '21: 401.3M Q1 '22: 435.5M Q2 '22: 454M Q3 '22: 477.7M Q4 '22: 467.5M Q1 '23: 456.9M Q2 '23: 459.4M Q3 '23: 466.8M Q4 '23: 490.3M Q1 '24: 498.7M Q2 '24: 511.2M Q3 '24: 516.7M Q4 '24: 530.5M Q1 '25: 545.5M Q2 '25: 551.9M Q3 '25: 567.5M Q4 '25: 576.7M Q1 '26: 583M Q2 '26: 591M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '20: 29.3M Q4 '20: 46.3M Q1 '21: 48.7M Q2 '21: 90.7M Q3 '21: 104.5M Q4 '21: 89.9M Q1 '22: 87.9M Q2 '22: 84.3M Q3 '22: 74.1M Q4 '23: 87.7M Q1 '24: 104M Q2 '24: 92.3M Q3 '24: -64.9M Q4 '24: -73.4M Q1 '25: -84.6M Q2 '25: -104.3M Q3 '25: 41.6M Q4 '25: 19.2M Q1 '26: 24.1M Q2 '26: 19.9M Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '20: 126.1M Q4 '20: 145.5M Q1 '21: 147.7M Q2 '21: 174.1M Q3 '21: 61.6M Q4 '22: 15.9M Q1 '23: -10.5M Q2 '23: -4.6M Q3 '23: 7M Q4 '23: 42M Q1 '24: 70.5M Q2 '24: 63.6M Q3 '24: -90.7M Q4 '24: -99.6M Q1 '25: -103.7M Q2 '25: -127.5M Q3 '25: 21.4M Q4 '25: 7M Q1 '26: 5.1M Q2 '26: 14.6M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 80M 160M 240M Q3 '21: 136.5M Q4 '21: 140.3M Q1 '22: 145M Q2 '22: 160.4M Q3 '22: 176.4M Q4 '22: 199.3M Q1 '23: 212.2M Q2 '23: 209.8M Q3 '23: 198.9M Q4 '23: 184.7M Q1 '24: 183.1M Q2 '24: 179.1M Q3 '24: 178.2M Q4 '24: 170.4M Q1 '25: 157.3M Q2 '25: 153.9M Q3 '25: 149.3M Q4 '25: 149.7M Q1 '26: 151.9M Q2 '26: 155.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

0 70M 140M 210M Q3 '21: 149.2M Q4 '21: 125.7M Q1 '22: 144.4M Q2 '22: 144.1M Q3 '22: 126.5M Q4 '22: 145.3M Q1 '23: 133.6M Q2 '23: 147.3M Q3 '23: 149.1M Q4 '23: 154.6M Q1 '24: 184.6M Q2 '24: 194.4M Q3 '24: 203.8M Q4 '24: 189.4M Q1 '25: 175.7M Q2 '25: 134.5M Q3 '25: 141.4M Q4 '25: 152M Q1 '26: 142.2M Q2 '26: 187.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

0 70M 140M 210M Q3 '21: 98.1M Q4 '21: 79.9M Q1 '22: 104M Q2 '22: 102.4M Q3 '22: 92.7M Q4 '22: 115.2M Q1 '23: 104.7M Q2 '23: 126.7M Q3 '23: 130.2M Q4 '23: 139.5M Q1 '24: 173.2M Q2 '24: 184.7M Q3 '24: 193.5M Q4 '24: 178.8M Q1 '25: 159.4M Q2 '25: 117.1M Q3 '25: 124.2M Q4 '25: 136.7M Q1 '26: 132.7M Q2 '26: 179.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 42.8M Q2 '20: 42.2M Q3 '20: 44.3M Q1 '21: 46M Q2 '21: 45.6M Q3 '21: 45.5M Q1 '22: 46.4M Q2 '22: 52.5M Q3 '22: 45.8M Q1 '23: 45.9M Q2 '23: 52.1M Q3 '23: 52.1M Q1 '24: 52.2M Q2 '24: 50.5M Q3 '24: 46.1M Q1 '25: 46.5M Q2 '25: 45.5M Q3 '25: 44.5M Q1 '26: 40.9M Q2 '26: 40.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: 2.84 Q4 '20: 3.28 Q1 '21: 3.32 Q2 '21: 3.91 Q3 '21: 1.36 Q4 '22: 0.34 Q1 '23: -0.24 Q2 '23: -0.13 Q3 '23: 0.12 Q4 '23: 0.83 Q1 '24: 1.45 Q2 '24: 1.33 Q3 '24: -2.01 Q4 '24: -2.15 Q1 '25: -2.24 Q2 '25: -2.74 Q3 '25: 0.49 Q4 '25: 0.15 Q1 '26: 0.12 Q2 '26: 0.35 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.